Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches
in Beneficial MicrobesSearch for other papers by J. Alard in
Current site
Google Scholar
Search for other papers by V. Peucelle in
Current site
Google Scholar
Search for other papers by D. Boutillier in
Current site
Google Scholar
Search for other papers by J. Breton in
Current site
Google Scholar
Search for other papers by S. Kuylle in
Current site
Google Scholar
Search for other papers by B. Pot in
Current site
Google Scholar
Search for other papers by S. Holowacz in
Current site
Google Scholar
Search for other papers by C. Grangette in
Current site
Google Scholar
Alterations in the gut microbiota composition play a key role in the development of chronic diseases such as inflammatory bowel disease (IBD). The potential use of probiotics therefore gained attention, although outcomes were sometimes conflicting and results largely strain-dependent. The present study aimed to identify new probiotic strains that have a high potential for the management of this type of pathologies. Strains were selected from a large collection by combining different in vitro and in vivo approaches, addressing both anti-inflammatory potential and ability to improve the gut barrier function. We identified six strains with an interesting anti-inflammatory profile on peripheral blood mononuclear cells and with the ability to restore the gut barrier using a gut permeability model based on Caco-2 cells sensitized with hydrogen peroxide. The in vivo evaluation in two 2,4,6-trinitrobenzene sulfonic acid-induced murine models of colitis highlighted that some of the strains exhibited beneficial activities against acute colitis while others improved chronic colitis. Bifidobacterium bifidum PI22, the strain that exhibited the most protective capacities against acute colitis was only slightly efficacious against chronic colitis, while Bifidobacterium lactis LA804 which was less efficacious in the acute model was the most protective against chronic colitis. Lactobacillus helveticus PI5 was not anti-inflammatory in vitro but the best in strengthening the epithelial barrier and as such able to significantly dampen murine acute colitis. Interestingly, Lactobacillus salivarius LA307 protected mice significantly against both types of colitis. This work provides crucial clues for selecting the best strains for more efficacious therapeutic approaches in the management of chronic inflammatory diseases. The strategy employed allowed us to identify four strains with different characteristics and a high potential for the management of inflammatory diseases, such as IBD.
-
Ameho, C.K., Adjei, A.A., Harrison, E.K., Takeshita, K., Morioka, T., Arakaki, Y., Ito, E., Suzuki, I., Kulkarni, A.D., Kawajiri, A. and Yamamoto, S., 1997. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41: 487-493.
'Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis ' () 41 Gut : 487 -493.
-
Barbara, G., Zecchi, L., Barbaro, R., Cremon, C., Bellacosa, L., Marcellini, M., De Giorgio, R., Corinaldesi, R. and Stanghellini, V., 2012. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. Journal of Clinical Gastroenterology 46 Suppl: S52-S55.
'Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome ' () 46 Journal of Clinical Gastroenterology : S52 -S55.
-
Bene, L., Falus, A., Baffy, N. and Fulop, A.K., 2011. Cellular and molecular mechanisms in the two major forms of inflammatory bowel disease. Pathology & Oncology Research 17: 463-472.
'Cellular and molecular mechanisms in the two major forms of inflammatory bowel disease ' () 17 Pathology & Oncology Research : 463 -472.
-
Burns, P., Alard, J., Hrdy, J., Boutillier, D., Paez, R., Reinheimer, J., Pot, B., Vinderola, G. and Grangette, C., 2016. Spray-drying process preserves the protective capacity of a breast milk-derived Bifidobacterium lactis strain on acute and chronic colitis in mice. Scientific Reports 7: 43211.
'Spray-drying process preserves the protective capacity of a breast milk-derived Bifidobacterium lactis strain on acute and chronic colitis in mice ' () 7 Scientific Reports : 43211.
-
Burns, P., Alard, J., Hrdy, J., Boutillier, D., Paez, R., Reinheimer, J., Pot, B., Vinderola, G. and Grangette, C., 2017. Spray-drying process preserves the protective capacity of a breast milk-derived Bifidobacterium lactis strain on acute and chronic colitis in mice. Scientific Reports 7: 43211.
'Spray-drying process preserves the protective capacity of a breast milk-derived Bifidobacterium lactis strain on acute and chronic colitis in mice ' () 7 Scientific Reports : 43211.
-
Chantret, I., Rodolosse, A., Barbat, A., Dussaulx, E., Brot-Laroche, E., Zweibaum, A. and Rousset, M., 1994. Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation. Journal of Cell Science 107 (Part 1): 213-225.
'Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation ' () 107 Journal of Cell Science : 213 -225.
-
Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2001. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Available at: http://tinyurl.com/8bccc3r.
-
Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B., 2007a. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 13: 236-243.
'Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria ' () 13 World Journal of Gastroenterology : 236 -243.
-
Foligne, B., Nutten, S., Steidler, L., Dennin, V., Goudercourt, D., A., M. and B., P., 2006. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Digestive Diseases and Sciences 51: 394-404.
'Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects ' () 51 Digestive Diseases and Sciences : 394 -404.
-
Foligne, B., Zoumpopoulou, G., Dewulf, J., Ben Younes, A., Chareyre, F., Sirard, J.C., Pot, B. and Grangette, C., 2007b. A key role of dendritic cells in probiotic functionality. PloS One 2: e313.
'A key role of dendritic cells in probiotic functionality ' () 2 PloS One : e313.
-
Ghouri, Y.A., Richards, D.M., Rahimi, E.F., Krill, J.T., Jelinek, K.A. and DuPont, A.W., 2014. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clinical and Experimental Gastroenterology 7: 473-487.
'Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease ' () 7 Clinical and Experimental Gastroenterology : 473 -487.
-
Hampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K., Albrecht, M., Mayr, G., De La Vega, F.M., Briggs, J., Gunther, S., Prescott, N.J., Onnie, C.M., Hasler, R., Sipos, B., Folsch, U.R., Lengauer, T., Platzer, M., Mathew, C.G., Krawczak, M. and Schreiber, S., 2007. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genetics 39: 207-211.
'A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 ' () 39 Nature Genetics : 207 -211.
-
Homer, C.R., Richmond, A.L., Rebert, N.A., Achkar, J.P. and McDonald, C., 2010. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn’s disease pathogenesis. Gastroenterology 139: 1630-1641, 1641 e1631-1632.
'ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn’s disease pathogenesis ' () 139 Gastroenterology : e1631 -1632.
-
Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J.P., Belaiche, J., Almer, S., Tysk, C., O’Morain, C.A., Gassull, M., Binder, V., Finkel, Y., Cortot, A., Modigliani, R., Laurent-Puig, P., Gower-Rousseau, C., Macry, J., Colombel, J.F., Sahbatou, M. and Thomas, G., 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411: 599-603.
'Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease ' () 411 Nature : 599 -603.
-
Langholz, E., Munkholm, P., Davidsen, M. and Binder, V., 1994. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107: 3-11.
'Course of ulcerative colitis: analysis of changes in disease activity over years ' () 107 Gastroenterology : 3 -11.
-
Macho Fernandez, E., Valenti, V., Rockel, C., Hermann, C., Pot, B., Boneca, I.G. and Grangette, C., 2011. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 60: 1050-1059.
'Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide ' () 60 Gut : 1050 -1059.
-
Machtaler, S., Knieling, F., Luong, R., Tian, L. and Willmann, J.K., 2015. Assessment of inflammation in an acute on chronic model of inflammatory bowel disease with ultrasound molecular imaging. Theranostics 5: 1175-1186.
'Assessment of inflammation in an acute on chronic model of inflammatory bowel disease with ultrasound molecular imaging ' () 5 Theranostics : 1175 -1186.
-
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., Roca, J. and Dore, J., 2006. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55: 205-211.
'Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach ' () 55 Gut : 205 -211.
-
Martin, R., Laval, L., Chain, F., Miquel, S., Natividad, J., Cherbuy, C., Sokol, H., Verdu, E.F., van Hylckama Vlieg, J., Bermudez-Humaran, L.G., Smokvina, T. and Langella, P., 2016. Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice. Frontiers in Microbiology 7: 608.
'Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice ' () 7 Frontiers in Microbiology : 608.
-
McCarroll, S.A., Huett, A., Kuballa, P., Chilewski, S.D., Landry, A., Goyette, P., Zody, M.C., Hall, J.L., Brant, S.R., Cho, J.H., Duerr, R.H., Silverberg, M.S., Taylor, K.D., Rioux, J.D., Altshuler, D., Daly, M.J. and Xavier, R.J., 2008. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease. Nature Genetics 40: 1107-1112.
'Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease ' () 40 Nature Genetics : 1107 -1112.
-
Michielan, A. and D’Inca, R., 2015. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators of Inflammation 2015: 628157.
'Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut ' () 2015 Mediators of Inflammation : 628157.
-
Moss, A.C., 2014. Residual inflammation and ulcerative colitis in remission. Gastroenterology and Hepatology 10: 181-183.
'Residual inflammation and ulcerative colitis in remission ' () 10 Gastroenterology and Hepatology : 181 -183.
-
Neau, E., Delannoy, J., Marion, C., Cottart, C.H., Labellie, C., Holowacz, S., Butel, M.J., Kapel, N. and Waligora-Dupriet, A.J., 2016. Three novel candidate probiotic strains with prophylactic properties in a murine model of cow’s milk allergy. Applied and Environmental Microbiology 82: 1722-1733.
'Three novel candidate probiotic strains with prophylactic properties in a murine model of cow’s milk allergy ' () 82 Applied and Environmental Microbiology : 1722 -1733.
-
Prosberg, M., Bendtsen, F., Vind, I., Petersen, A.M. and Gluud, L.L., 2016. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. Scandinavian Journal of Gastroenterology 51: 1407-1415.
'The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis ' () 51 Scandinavian Journal of Gastroenterology : 1407 -1415.
-
Saez-Lara, M.J., Gomez-Llorente, C., Plaza-Diaz, J. and Gil, A., 2015. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Research International 2015: 505878.
'The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials ' () 2015 Biomed Research International : 505878.
-
Sartor, R.B., 2004. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633.
'Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics ' () 126 Gastroenterology : 1620 -1633.
-
Seth, A., Yan, F., Polk, D.B. and Rao, R.K., 2008. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. American Journal of Physiology – Gastrointestinal and Liver Physiology 294: G1060-G1069.
'Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism ' () 294 American Journal of Physiology – Gastrointestinal and Liver Physiology : G1060 -G1069.
-
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L.G., Gratadoux, J.J., Blugeon, S., Bridonneau, C., Furet, J.P., Corthier, G., Grangette, C., Vasquez, N., Pochart, P., Trugnan, G., Thomas, G., Blottiere, H.M., Dore, J., Marteau, P., Seksik, P. and Langella, P., 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the USA 105: 16731-16736.
'Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients ' () 105 Proceedings of the National Academy of Sciences of the USA : 16731 -16736.
-
Spor, A., Koren, O. and Ley, R., 2011. Unravelling the effects of the environment and host genotype on the gut microbiome. Nature Reviews Microbiology 9: 279-290.
'Unravelling the effects of the environment and host genotype on the gut microbiome ' () 9 Nature Reviews Microbiology : 279 -290.
-
Stappenbeck, T.S. and McGovern, D.P., 2016. Paneth cell alterations in the development and phenotype of Crohn’s disease. Gastroenterology 152: 322-326.
'Paneth cell alterations in the development and phenotype of Crohn’s disease ' () 152 Gastroenterology : 322 -326.
-
Swidsinski, A., Ladhoff, A., Pernthaler, A., Swidsinski, S., Loening-Baucke, V., Ortner, M., Weber, J., Hoffmann, U., Schreiber, S., Dietel, M. and Lochs, H., 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54.
'Mucosal flora in inflammatory bowel disease ' () 122 Gastroenterology : 44 -54.
-
Vivinus-Nebot, M., Frin-Mathy, G., Bzioueche, H., Dainese, R., Bernard, G., Anty, R., Filippi, J., Saint-Paul, M.C., Tulic, M.K., Verhasselt, V., Hebuterne, X. and Piche, T., 2014. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63: 744-752.
'Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation ' () 63 Gut : 744 -752.
-
Wallace, J.L., MacNaughton, W.K., Morris, G.P. and Beck, P.L., 1989. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96: 29-36.
'Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease ' () 96 Gastroenterology : 29 -36.
-
Whelan, K. and Quigley, E.M., 2013. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Current Opinion in Gastroenterology 29: 184-189.
'Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease ' () 29 Current Opinion in Gastroenterology : 184 -189.
Supplementary Materials
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 0 | 0 | 0 |
| Gesamttextansichten | 584 | 239 | 35 |
| PDF-Downloads | 584 | 220 | 16 |
New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches
in Beneficial MicrobesSearch for other papers by J. Alard in
Current site
Google Scholar
PubMed
Search for other papers by V. Peucelle in
Current site
Google Scholar
PubMed
Search for other papers by D. Boutillier in
Current site
Google Scholar
PubMed
Search for other papers by J. Breton in
Current site
Google Scholar
PubMed
Search for other papers by S. Kuylle in
Current site
Google Scholar
PubMed
Search for other papers by B. Pot in
Current site
Google Scholar
PubMed
Search for other papers by S. Holowacz in
Current site
Google Scholar
PubMed
Search for other papers by C. Grangette in
Current site
Google Scholar
PubMed
Alterations in the gut microbiota composition play a key role in the development of chronic diseases such as inflammatory bowel disease (IBD). The potential use of probiotics therefore gained attention, although outcomes were sometimes conflicting and results largely strain-dependent. The present study aimed to identify new probiotic strains that have a high potential for the management of this type of pathologies. Strains were selected from a large collection by combining different in vitro and in vivo approaches, addressing both anti-inflammatory potential and ability to improve the gut barrier function. We identified six strains with an interesting anti-inflammatory profile on peripheral blood mononuclear cells and with the ability to restore the gut barrier using a gut permeability model based on Caco-2 cells sensitized with hydrogen peroxide. The in vivo evaluation in two 2,4,6-trinitrobenzene sulfonic acid-induced murine models of colitis highlighted that some of the strains exhibited beneficial activities against acute colitis while others improved chronic colitis. Bifidobacterium bifidum PI22, the strain that exhibited the most protective capacities against acute colitis was only slightly efficacious against chronic colitis, while Bifidobacterium lactis LA804 which was less efficacious in the acute model was the most protective against chronic colitis. Lactobacillus helveticus PI5 was not anti-inflammatory in vitro but the best in strengthening the epithelial barrier and as such able to significantly dampen murine acute colitis. Interestingly, Lactobacillus salivarius LA307 protected mice significantly against both types of colitis. This work provides crucial clues for selecting the best strains for more efficacious therapeutic approaches in the management of chronic inflammatory diseases. The strategy employed allowed us to identify four strains with different characteristics and a high potential for the management of inflammatory diseases, such as IBD.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 0 | 0 | 0 |
| Gesamttextansichten | 584 | 239 | 35 |
| PDF-Downloads | 584 | 220 | 16 |
